Member Info for Cebo-456

D-O - Another three plus a couple under evaluation. But agree.

Iceman, interview today - are you sure?. Those things usually take a little bit of time to set up although I know that the Company will be keen to put some meat on the bone for those that are "prepared to listen".
I have found Suzy to be always extremely professional and always replied to emails in a very timely manner, including this morning. If anyone has any real concerns then I suggest that they may want to get in touch with the Company directly - the Company obviously can't and won't divulge any info not in the public domain, nor would I expect them to, but still a worthwhile exercise - (just don't post any replies on this or any other public forum, it is unprofessional and will only erode trust between the Company and PI's).
I do look forward to an interview in the next day or so or when they get a slot.
GLA, those that are prepared to listen and have done their research will realise the importance of this news and that it was the next step in the process and needed to happen.
D

It doesn't help that many muppets on here cannot read an RNS - this RNS is formalising the Service Agreement tjat was alluded to on the 02nd Nov RNS. This RNS states that the Company also believes everything is still on track and moving forward with TheoremRx with the sub licence deal - subject to TheoremRx completing their own fund raise.

The reason there is no mention of the upfront payments on the RNS (as some have highlighted) is because that is part of the licensing deal, not this Service agreement. So despite what some wrote earlier - the "deal" for licensing Val201 hasn't been amended and the upfront payments will still be paid to Val.

This RNS says that there is a slight delay in TheoremRx signing but all is still on track with the Licencing deal, it also says that other areas are progressing well and that T'Rx have now formally agreed to pay for Val advisory services going forward.

Pretty sure Suzy will confirm this in an interview shortly.

MD, "by Friday", maybe - I am sure that Suzy will be on the blower to Ken Sorensen asking for an update today. I would however prefer to see the SP back into the 40's before news - that way the II's will pay more and any of the bed-wetters on here and those predicting a drop this week (to buy in cheaper) will pay substantially more on any positive RNS.

Triple Negative Breast Cancer - bloody auto correct.

What do we have - in my opinion we have real short, medium and long term triggers that should see the SP potentially a lot higher than where it is now - bear in mind that a few weeks ago the SP touched mid 60"s based on a letter of intent to sub license Val 201.
Short term (days or weeks at most) we could/should recieve news that the deal with TheoremRx has been signed and first payments recieved - this will basically not only fund all operating costs, but also fund the current pipeline and any current and future evaluations.
Short to medium term - hopefully the Japanese Farma will take Val301 forward, if not then another commercial deal may be announced.
Val 401 (lung and pancreatic cancer) is ready to go and any tie-in with med Biothech/SPV's will be huge news.
Medium term (Q2/3) should see the triple-ne' breathing cancer compound eval complete and moved to pre clinical trials - this in my opinion is one where Big Pharma could come in for pre-phase 1 (early 2023 potentially) which would be transformational to the Company.
II's will arrive when Val201 licence is signed and income generation guaranteed from TheoremRx.
Fingers crossed for news soon.

DK and others - you will get your RNS when things are signed or there is a known reason for any delay to the licensing agreement- any other RNS would be as amateur as those posting on here asking for one.

Not disappointed at all, not even a tad. Val have done everything their end, just awaiting Uncle Sam to do his.
No change to the direction - expectation is year end, and delays to this will be RNS'd. So if TheoremRx ask for another month or the licence needs further tweaking that causes any delay then I expect an RNS - otherwise nothing has changed and we will hear news when the deal is signed. So unless their is substantial delays or the licence agreement isn't going through then I see absolutely no reason for any RNS until we see this finalised. Year end was always ambitious, given Thanksgiving and Christmas - I don't think it will drag too far into Q1/22 in fact early Jan will do just fine. News today would have been lost over the new year period, releasing the RNS when the markets open Jan will have the greatest impact on the SP, good or bad.

Aye, ok - we shall see.

Why, - TheoremRx are not listed, so no need.
Also no need to wait till 0700hrs the next morning if they get confirmation intra-day - as price sensitive info should be released as soon as possible.

I don't believe for one minute that any small delay will need to be RNS'd. If the deal is off and that is still a possibility (despite what some on here say), then it needs an RNS. - and it is because of that possibility that the SP is still <40p.
There is also no way that we will see any real II action until everything is complete - fund managers cannot take a risk on something that has even a 10% chance of not getting the expected signatures. They would rather pay 80% more to get a 20% profit than risk having to answer to their clients as to why they bought before the deal was signed, sealed and delivered.
Now I firmly believe, as per my post a few days ago that everything is still pointing to a positive resolution and that in the next few trading days - tomorrow or early in the new year we shall hear the good news - but if it drags on another couple of weeks then so be it.

I think many missed Suzy's interview with Scott on BRR media just before Christmas - Suzy, from memory, discussed that the signatures were close, hopefully this year, if not very soon. She also talked about 2022, Val creating revenue and the options they have to bring on board another two potential game-changing (my words) compounds.
We are days, not months away from Val201 news - along with potential other transformational deals next year.

This hit mid 60's from memory when the Letter of intent was RNS'd 2nd Nov 21. If and when they sign the licencing agreement signed then we should see that again and then some.

Fat fingers, small phone and bloody auto correct (time-lines / not, not nit ;-) etc). but you get the just, hopefully.

Although we were never informed officially of the period grated to TheoremRx to conduct their DD, we were told that Val expected the first payments by year end. Since taking over the CEO's role - Suzy has delivered and timeliness have nit slipped - i think it is close and that VRX will sign the Doc, followed by the first payments.
Val also tweaked and restated the Val201 license from CRT earlier this month at (I believe) the request of theoremRx, probably a perquisites to signing.
CRT have also been asked to approve (licence requirement) Val and TRX proceeding to full license - this wouldnt have happened if Theorem hadn't raised the funds and completed or were close to completing their due diligence .
All this, I believe, points towards the deal going through and first payments recieved - I personally think it will be be before Christmas and certainly before year end.
Great work Suzy and the team, have a well deserved festive break ready for another great year 2022.
D

Cat5, not sure what point you are making by highlighting the distance between BP licence and Hurricane's ???? most investors know or should know exactly where the acerage is.
Potatohead. Thats incorrect also - they do not need to make an offer for the highest price paid - only the highest price that they have paid for the shares - and that would include any bought from CA. CA certainly haven't paid over 5p for their shares in the last 12 months.
Sense men, not quite correct either as in most cases your 7p scenario would still count whether open market or not - but even if it did, the bidder would still need to convince a whole lot more shareholders to sell them their shares - going above the 30% threshold doesn't automatically entitle then to buy the remaining shares at any set price.

FWIW - I do not hold any here but still keep an interest for old times sake.

And those with DMA will likely be looking at the bigger picture. After the Avacta RNS, I thought bothe they and Abingdon H would rise minimum of 50% today - and they still might. It will need confirmation now of the orders to get this anywhere close to the IPO price of a quid. That said with the small MC, this could move fast.

I suggest that they are switching initially to PCR for air travel so they can differentiate between the Delta and the Omicron variants - as the LFTs do not.
Let's also hope that not only does the VISITECT test, but also the current Gov supplied LFT's, detect the new variant - if not then not only do the UK Gov have an issue (and a $hitload of even more useless chinese tests to bin), so will most other countries - and a load of Omicron "friendly" LFT's may be needed.
Who said the pandemic was over, this latest variant should show that a UK diagnostic capability is even more essential, unfortunately the UK Gov have fallen far short - if Boris and the DHSC do come back looking for capacity then I hope that UK manufacturers call the shots with decent contracts and legally binding guarantees going forward.

The very fact that ODX needed to take legal advice to find out if the contract had ended beggars belief, particularly as they were in "regular discussions with the DHSC" - I suggest that shows that the DHSC were just as clueless and were waiting for the UK Gov to make decisions on future LFT usage and policy.
Now with the new omicron variant everything is up in the air - no doubt policy will revert to target testing areas with LFT's where the new variant is detected, with any positives being confirmed by PCR. It may be that the free LFT's will be again extended, who knows. Was it this sort of scenario (plan B to secure or supplement the Chinese supplied plan A) that the contract was initially set up for? - possibly obviously the company and the DHSC have no idea, not even sure the UK Gov do.
I only watched the first half hour of the presentation (due to other commitments) and although Chris came across better than Colin, which wasn't hard, it does not make him ODX CEO material - what i though was interesting was when Chris mentioned and stressed on several occasions, his M&A experience with previous positions he has held !!!! FWIW, I am not calling for Colin to go, not yet anyway. - Colin is possibly naive and maybe lacking experience, and he certainly won't make a fortune on the after-dinner speaking circuit - but I don't think he is dishonest and I think changing CEO now would not do the company or the SP any favours.
Anyway, enjoy the rest of the weekend, I think that the ODX roller coaster ride has a few more surprises in store for us all - let's hope so :-)

Yep, and the directors all bought in at the placing price - the Company now have the funds that will attract the investments and contracts. Significantly over subscribed. :-). Just a shame that the allocation for current private investors is so low as I think this will be taken up fully - depending obviously where the SP is at the time.